RCKT
Rocket Pharmaceuticals, Inc.
There isn't enough reported data to score RCKT yet.
RCKT Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
RCKT's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
RCKT PE Valuation
RCKT has no meaningful PE right now: it lost money over the past year.
RCKT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect RCKT's losses to grow, with revenue declining. However, they disagree widely on these estimates.
RCKT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.15 | +$2.10 |
| Q2 2026 | -$0.17 | +$2.34 |
| Q1 2026 | -$1.87 | +$0.76 |
| Q4 2025 | -$2.01 | +$0.72 |
| Q3 2025 | -$2.25 | +$0.48 |
| Q2 2025 | -$2.51 | +$0.26 |
| Q1 2025 | -$2.63 | +$0.22 |
| Q4 2024 | -$2.73 | +$0.19 |
RCKT is still losing money, but far less than before: $0.15 per share over the past year, against $3.32 at its worst in early 2023.
RCKT Quarterly Revenue
RCKT's revenue is shrinking: $0 last quarter.
RCKT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$39.2M | +$11.2M |
| Q2 2026 | -$39.6M | +$9.4M |
| Q1 2026 | -$45.5M | +$10.7M |
| Q4 2025 | -$34.9M | +$12.3M |
| Q3 2025 | -$50.4M | +$3.3M |
| Q2 2025 | -$49M | +$6.7M |
| Q1 2025 | -$56.2M | +$2.7M |
| Q4 2024 | -$47.3M | -$13.3M |
RCKT has burned cash in almost every quarter: −$159M over the past year, against −$203M the year before.
RCKT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -867K shares |
| 1 year | +1.9% | +2.1M shares |
| 3 years | +38% | +31M shares |
| 5 years | +78% | +49.8M shares |
| Available history | +132% | +64.6M shares |
RCKT has 114M diluted shares, up 1.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | $72,000 |
RCKT Net Leverage
RCKT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RCKT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.6 | Neutral |
| Stochastic | 13.2 | Oversold |
RCKT's weekly RSI is 39 (neutral) and its Stochastic is 13 (oversold).
RCKT PE vs Healthcare Sector
RCKT has no meaningful PE right now: it lost money over the past year.
RCKT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.43 | 1.6% below |
| 20 week MA | $3.10 | 23% below |
| 50 week MA | $3.37 | 29% below |
| 100 week MA | $4.58 | 48% below |
| 200 week MA | $12.8 | 81% below |
RCKT is in a downtrend: it's below all five of its weekly moving averages, and 81% below its 200-week average.
RCKT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.1 | $56.7 | +136% |
| 2021 | $56.7 | $24.0 | -58% |
| 2022 | $24.0 | $18.2 | -24% |
| 2023 | $18.2 | $30.0 | +65% |
| 2024 | $30.0 | $11.8 | -61% |
| 2025 | $11.8 | $3.48 | -70% |
| 2026 YTD | $3.48 | $2.39 | -31% |
RCKT's yearly returns have swung widely, from +136% in 2020 to −70% in 2025. It's down 31% so far in 2026.